GeneTex’s SARS-CoV-2 Spike RBD Antibodies Effectively Inhibit Viral Entry

     Using the SARS-CoV-2 receptor-binding domain (RBD) as an immunogen, GeneTex has generated three recombinant monoclonal antibodies that effectively inhibit infection of Vero E6 cells by SARS-CoV-2 (unpublished data). Additional data show that these antibodies significantly decrease SARS-CoV-2 pseudovirus entry into ACE2-overexpressing 293T cells, with one having an IC50 value of 1.585 ng/ml (10.6 pM) (see figure below).  Available antibodies include one with a human IgG backbone ([HL1003-HU] GTX635866) and two others in a rabbit IgG format ([HL1003] GTX635792; [HL1004] GTX635793), offering flexibility for various experimental applications.

SARS-CoV-2 (COVID-19) Spike RBD antibody [HL1003-HU] (GTX635866) effectively neutralizes SARS-CoV-2 pseudovirus entry into human cells. (A) Tested antibodies were serially diluted five-fold in culture medium starting at 0.32 ng/ml, and 50 ul of each antibody dilution was added to 10 ul (1000 TCID50) of SARS-CoV-2 pseudovirus. Each mixture was then added to 293T cells overexpressing human ACE2. After 60 hours, the cells were collected, lysed, and luciferase activity assays were performed. (B, C) The half-maximal inhibitory concentrations (IC50) of SARS-CoV-2 (COVID-19) Spike RBD antibody [HL1003-HU] (GTX635866) (B) and SARS-CoV-2 (COVID-19) Spike RBD antibody [HL1003] (GTX635792) (C) are indicated.

     The Coronavirus Disease 2019 (COVID-19) pandemic, caused by SARS-CoV-2, has been devastating to the world’s citizens and economies. Recent data from the World Health Organization (WHO) documents almost 64 million confirmed cases with nearly 1.5 million deaths (https://covid19.who.int/). The actual number of COVID-19 cases is certainly higher due to undercounting of mild and asymptomatic cases, as well as the limited capacity of detection tools. Prevention and treatment of this disease will require basic and clinical research supporting the development and evaluation of vaccines and antiviral therapies, including neutralizing monoclonal antibodies (1,2).

     GeneTex is proud to offer the most comprehensive, well-validated, and widely used catalog of SARS-CoV-2 reagents, including antibodies (validated for applications such as WB, ICC/IF, IHC, ELISA, and FCM), recombinant proteins, transfected FFPE cell blocks, and other related products. These reagents have been cited in numerous SARS-CoV-2/COVID-19 studies, including the SARS-CoV-2 (COVID-19) Spike antibody [1A9] (GTX632604) and SARS-CoV-2 (COVID-19) Nucleocapsid antibody (GTX135357) used for multiple purposes in reports published in the NEJM, Cell, and The Lancet.

References:

1. Signal Transduct Target Ther. 2020 Sep 22;5(1):212.
2. Adv Mater. 2020 Oct 28;e2005637.